Skip to content

A Randomized Trial on the Efficacy of Perioperative Octreotide in Endoscopic Papillectomy

Efficacy of Perioperative Octreotide Acetate in Endoscopic Papillectomy for Ampullary Tumors: A Single-Center Randomized Superiority Exploratory Trial - OCTOPUS Study

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs051250180
Enrollment
58
Registered
2026-01-07
Start date
2026-03-04
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ampullary tumor Ampullary tumor

Interventions

Subcutaneous administration of Octreotide acetate
Octreotide

Sponsors

Kai Yugo
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Diagnosis of duodenal adenoma or intramucosal adenocarcinoma by preoperative endoscopic forceps biopsy or endoscopic observation. In cases of adenocarcinoma, endoscopic observation or endoscopic ultrasound reveals that the cancer is confined to the mucosal layer. Age is 18 or over. No severe organ dysfunction. Performance Status (ECOG) is 0, 1 or 2. Written informed consent is obtained.

Exclusion criteria

Exclusion criteria: Poorly controlled diabetes mellitus. Continuous use of Cyclosporin or Bromocriptine. Active other organ cancer that cannot be cured. Severe psychiatric disease. Active infectious disease. Participating in other interventional study. Patients judged inappropriate by investigator or attending doctor.

Design outcomes

Primary

MeasureTime frame
Incidence rate of postoperative complications (pancreatitis, hemorrhage, perforation) occurring within 30 days after endoscopic papillectomy

Secondary

MeasureTime frame
1. Incidence of intraoperative complications 2. Incidence of all complications within 30 days postoperatively 3. Incidence of treatment-related adverse events 4. Duration of fasting 5. Length of hospital stay 6. Changes in blood glucose levels before and after octreotide acetate administration

Contacts

Public ContactShunsuke Yoshii

Osaka International Cancer Institute

shunsuke.yoshii@oici.jp+81-6-6945-1181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026